Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma

Table 1 Patient data before initiation of radiotherapy (n = 94)

Data	n (%)
Age (yr)
< 60	78(83.0)
≥ 60	16(17.0)
Gender
Male	84(89.4)
Female	10(10.6)
Alpha-fetoprotein
> 400 ng/mL	64 (68.1)
≤ 400 ng/mL	30(31.9)
Child-Pugh classification for cirrhosis of liver
Class A	43(45.7)
Class B	51(54.3)
Karnofsky performance score
> 70	90(95.7)
< 70	4(4.3)
Okuda stage
I	63(67.0)
II	31(33.0)
Tumor size (cm)
< 5	17(18.1)
5-10	40(42.6)
> 10	37(39.3)
Tumor type
Massive	66(70.2)
Multinodular	28(29.8)
PVT
Yes	12(12.8)
No	82(87.2)
Albuminemia
< 3 g/dL	15(16.0)
> 3 g/dL	79(84.0)
Bilirubinemia
< 3 mg/dL	29(30.9)
> 3 mg/dL	65(69.1)
Chronic hepatitis in serum virology
Type B	90(95.7)
Type C	4(4.3)
Radiation dose
60 Gy	34(36.2)
56 Gy	34(36.2)
48 Gy	26(27.6)
TACE
1 fraction	59(62.8)
> 1 fraction	35(37.2)

Table 2 CT response of HCC to 3D-CRT combined with TACE

Response	No of patients (%)
Complete	12(12.8)
Partial	73(77.7)
Stable disease	6(6.4)
Progressive disease	3(3.1)

Table 3 Univariate and multivariate analyses of prognosis factors for overall survival

Univariate analysis	Multivariate analysis
	P	R (95%CI)	P
Age (yr)	0.026	2.377	0.024
Tumor size	0.000	6.183	0.000
Radiation dose	0.000	0.491	0.001
Child-Pugh classification	0.010
for cirrhosis of liver
Karnofsky performance status	0.913
Okuda stage	0.008
Gender	0.202
Tumor type	0.029
PVT	0.235
Albuminemia	0.035
Bilirubinemia	0.305
Chronic hepatitis in serum virology	0.060
Alpha-fetoprotein	0.861
TACE	0.892

HR: Hazard ratio; 95% CI: Confidence interval.